March 21

(The Wall Street Journal) A Food and Drug Administration panel backed a novel, noninvasive device that uses an electrical field designed to blast apart cancer cells as a potential treatment for brain cancer amid concerns about how well the device works.  The device, called the NovoTTF (for tumor treating fields), was designed by a private firm, NovoCure Ltd., which has operations in Israel and the U.S. It is being developed for use in patients with glioblastoma, a common form of brain cancer, initially for use after standard treatments fail.  For the complete report, visit